Akron Bio debuts new plasmid DNA plant on quest to ease regenerative medicine bottlenecksnews2022-04-14T17:59:41+00:00April 14th, 2022|Fierce Pharma|
Merck evades ‘aggressive marketing’ claims tied to once-dominant Zostavax shotnews2022-04-14T15:14:28+00:00April 14th, 2022|Fierce Pharma|
Novartis’ Sandoz strikes AbbVie’s popular eye pressure drug with generic launchnews2022-04-14T15:07:24+00:00April 14th, 2022|Fierce Pharma|
Latecomer Valneva scores approval for COVID-19 vaccine in U.K. Can the shot find a niche?news2022-04-14T14:17:39+00:00April 14th, 2022|Fierce Pharma|
Bluebird’s $2.1M gene therapy prospect Zynteglo gets cost watchdog’s backingnews2022-04-14T13:38:31+00:00April 14th, 2022|Fierce Pharma|
VectorBuilder to spend $500M to construct gene therapy manufacturing site in Chinanews2022-04-14T13:15:28+00:00April 14th, 2022|Fierce Pharma|
Regeneron’s bid for COVID-19 drug’s full approval hits snag as FDA extends reviewnews2022-04-14T13:15:01+00:00April 14th, 2022|Fierce Pharma|
Johnson & Johnson’s new Stelara ‘UnstoppaBOLD’ campaign zeroes in on empowerment and diversitynews2022-04-14T12:13:26+00:00April 14th, 2022|Fierce Pharma|
Arcutis Biotherapeutics finds psoriasis isn’t just skin deep, with Harris Poll also pointing to a gap in provider communicationnews2022-04-14T11:55:08+00:00April 14th, 2022|Fierce Pharma|
Bausch Health slapped by FDA for ‘concerning’ failure to show psoriasis cream’s risks on Montel Williams’ shownews2022-04-14T09:40:59+00:00April 14th, 2022|Fierce Pharma|
